LGND has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LGND has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Ligand Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) is 18.88.
For the Biotechnology subindustry, Ligand Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.
Ligand Pharmaceuticals (NAS:LGND) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.
Martine Zimmermann | director | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121 |
Todd C Davis | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Andrew Reardon | officer: CHIEF LEGAL OFFICER & | C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Octavio Espinoza | officer: Chief Financial Officer | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121 |
John W Kozarich | director | 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
John L Higgins | officer: CEO & President | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Jason Haas | director | C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
Matthew W Foehr | officer: EVP and COO | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
John L Lamattina | director | 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454 |
Jennifer R. Cochran | director | C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121 |
Charles S Berkman | officer: Asso. Gen. Counsel, Secretary | 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037 |
Sunil Patel | director | 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
From GuruFocus
By Business Wire Business Wire • 02-18-2023
By Business Wire Business Wire • 02-06-2023
By Business Wire • 09-22-2023
By Business Wire Business Wire • 04-24-2023
By Business Wire • 07-27-2023
By Business Wire • 09-27-2023
By PRNewswire PRNewswire • 02-16-2023
By Business Wire • 09-21-2023
By Business Wire • 08-08-2023
By Business Wire Business Wire • 12-13-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.